

Laboratory Overview

VERI/O Laboratory Services has demonstrated a strong track record in the support of retrospective studies for our biopharma clients. Make VERI/O Laboratory Services your partner for your next research study, translational medicine application, or diagnostic development project.

- Retrospective sample processing
- Pilot studies
- Custom assay development
- Disease-specific validation studies

Features and Benefits

- Molecular profiling expertise:
highly trained and dedicated staff delivering high-quality data leveraging the advantages of the HTG EdgeSeq technology
- Focused on turnaround times:
receive a customized report on tens to thousands of biomarkers to meet your timelines
- Deferred investment cost:
all the advantages of targeted next-generation sequencing (NGS)-based results without the capital investments, training, and labor costs



“HTG has been a true partner and collaborator in our drug development program and we truly appreciate their support to meet the regulatory filing deadline for one of our key drug products.”

~ Senior Manager, Clinical Biomarkers-Oncology, Global Pharma Partner


RUO* Assays Offered by VERI/O Laboratory Services

HTG EdgeSeq ALK <i>Plus</i> Assay	ALK rearrangement status and ROS1, RET, NTRK1, cMET, HER2 data
HTG EdgeSeq Custom Assay Design	Specialized service to meet your individual project goals
HTG EdgeSeq DLBCL Cell of Origin Assay	Subtype diffuse large B-cell lymphoma samples (ABC vs. GCB)
HTG EdgeSeq EGFR, KRAS, BRAF Mutation Assay	New HTG EdgeSeq DNA chemistry
HTG EdgeSeq Immuno-Oncology Assay	549 genes implicated in the host immune response to tumors
HTG EdgeSeq miRNA Whole Transcriptome Assay	2,083 miRNA human transcripts
HTG EdgeSeq Oncology Biomarker Panel	2,560 genes, 24 groups and pathways
HTG EdgeSeq PATH Assay	New Multiplexed gene expression complement to IHC testing

*Research Use Only (RUO)

“It’s been a pleasure working with HTG. The HTG EdgeSeq technology is allowing us to maximize the amount of data we can generate from limited and precious clinical specimens.”

~ Manager, Biomarker Development Translational Oncology, Global BioPharma Company




Sample Requirements

VERI/O Laboratory Services accepts a wide variety of clinical samples for testing including formalin-fixed, paraffin-embedded (FFPE) tissue, plasma/serum, PAXgene, extracted RNA, and cells. Sample types and amounts are specific to each assay and customer project.

For more information contact HTG Molecular Diagnostics at info@htgmolecular.com or your local HTG Molecular Diagnostics representative.

Partner with HTG

VERI/O Laboratory Services supports biomarker research and companion diagnostic development using HTG’s extraction-free technology and growing portfolio of profiling assays. Results are provided for retrospective samples and are not for use in diagnostic procedures.



Learn More

The HTG EdgeSeq system has a number of key advantages, including multiplexing from tens to thousands of biomarkers in a single sample; very low sample input requirements; simple, extraction-free sample preparation; automated workflow; and simplified data output.

VERI/O Laboratory Services is a powerful solution providing gene expression profiling results for researchers, laboratory staff, and biomarker leads pursuing discovery, translational medicine, and other oncology applications.

For more information contact HTG Molecular Diagnostics at 1-877-289-2615, info@htgmolecular.com, or contact your local HTG Molecular Diagnostics representative. Visit www.htgmolecular.com.



HTG Molecular Diagnostics, Inc.
3430 E. Global Loop, Tucson, AZ 85706, USA
Call 1-877-289-2615 Fax 1-520-547-2837
info@htgmolecular.com or feedback@htgmolecular.com

Service and Support 1-877-507-3259
Orders orders@htgmolecular.com

For research use only. Not for use in diagnostic procedures.

In the U.S. and other applicable jurisdictions, HTG EdgeSeq and VERI/O are trademarks of HTG Molecular Diagnostics, Inc. Any other trademarks or trade names used herein are the intellectual property of their respective owners.

Rev 4: 5-MAY-2017